Novo Nordisk A/S’s (NOVOB) Neutral Rating Reaffirmed at JPMorgan Chase & Co.

Novo Nordisk A/S (SWX:NOVOB)‘s stock had its “neutral” rating restated by JPMorgan Chase & Co. in a note issued to investors on Friday, October 12th.

Separately, Goldman Sachs Group restated a “buy” rating on shares of Novo Nordisk A/S in a research report on Wednesday, October 10th.

NOVOB stock remained flat at $€47.79 ($55.57) during midday trading on Friday. Novo Nordisk A/S has a 52 week low of €33.43 ($38.87) and a 52 week high of €56.35 ($65.52).

Recommended Story: Find a Trading Strategy That Works

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply